Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: A nested cohort study
MetadataShow full item record
© 2018 The Author(s). Background: Both anaemia and red blood cell (RBC) transfusion are common and associated with adverse outcomes in patients admitted to the intensive care unit (ICU). The aim of this study was to determine whether serum hepcidin concentration, measured early after ICU admission in patients with anaemia, could identify a group in whom intravenous (IV) iron therapy decreased the subsequent RBC transfusion requirement. Methods: We conducted a prospective observational study nested within a multicenter randomized controlled trial (RCT) of IV iron versus placebo. The study was conducted in the ICUs of four tertiary hospitals in Perth, Western Australia. Critically ill patients with haemoglobin (Hb) of <100g/L and within 48h of admission to the ICU were eligible for participation after enrolment in the IRONMAN RCT. The response to IV iron therapy compared with placebo was assessed according to tertile of hepcidin concentration. Results: Hepcidin concentration was measured within 48h of ICU admission in 133 patients. For patients in the lower two tertiles of hepcidin concentration (<53.0µg), IV iron therapy compared with placebo was associated with a significant decrease in RBC transfusion requirement [risk ratio 0.48 (95% CI 0.26-0.85), p=0.013]. Conclusions: In critically ill patients with anaemia admitted to an ICU, baseline hepcidin concentration predicts RBC transfusion requirement and is able to identify a group of patients in whom IV iron compared with placebo is associated with a significant decrease in RBC transfusion requirement.
Showing items related by title, author, creator and subject.
Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: A randomized trial of IV iron in critical illnessThe, I.; Litton, E.; Baker, S.; Erber, W.; Farmer, Shannon; Ferrier, J.; French, C.; Gummer, J.; Hawkins, D.; Higgins, A.; Hofmann, Axel; De Keulenaer, B.; McMorrow, J.; Olynyk, John; Richards, T.; Towler, S.; Trengove, R.; Webb, S.; The, A. (2016)Purpose: Both anaemia and allogenic red blood cell transfusion are common and potentially harmful in patients admitted to the intensive care unit. Whilst intravenous iron may decrease anaemia and RBC transfusion requirement, ...
The IRONMAN trial: a protocol for a multicentre randomised placebo-controlled trial of intravenous iron in intensive care unit patients with anaemiaLitton, E.; Baker, S.; Erber, W.; French, C.; Ferrier, J.; Hawkins, D.; Higgins, A.; Hofmann, Axel; De Keulenaer, B.; Farmer, Shannon; McMorrow, J.; Olynyk, John; Richards, T.; Towler, Simon; Webb, S. (2014)Background: Allogeneic red blood cell (RBC) transfusion is associated with significant increases in mortality and major morbidity in patients admitted to the intensive care unit, and the blood supplies it requires are an ...
Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trialGummer, J.; Trengove, R.; Pascoe, E.; Badve, S.; Cass, A.; Clarke, P.; McDonald, S.; Morrish, A.; Pedagogos, E.; Perkovic, V.; Reidlinger, D.; Scaria, A.; Walker, R.; Vergara, L.; Hawley, C.; Johnson, D.; Olynyk, John; Ferrari, P. (2017)Background: Pentoxifylline has been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the Handling Erythropoietin ...